{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104972",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104972",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for imipramine and CYP2D6",
  "relatedChemicals" : [ {
    "objCls" : "Chemical",
    "@id" : "https://www.pharmgkb.org/data/chemical/PA449969",
    "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
    "id" : "PA449969",
    "name" : "imipramine"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA128",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA128",
    "symbol" : "CYP2D6",
    "name" : "cytochrome P450, family 2, subfamily D, polypeptide 6"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>The Dutch Pharmacogenetics Working Group Guideline for imipramine recommends to reduce the dose for CYP2D6 poor and intermediate metabolizer patients, and monitor imipramine and desipramine plasma concentrations. Select an alternative drug for CYP2D6 ultrarapid metabolizers.</p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for imipramine based on CYP2D6 genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  They recommend reducing the dose for poor and intermediate metabolizer patients, and selecting an alternative drug for ultra metabolizers.</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Phenotype (Genotype) </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> PM (2 inactive alleles) </td><td> Reduce dose by 70% and monitor imipramine and desipramine plasma concentrations. </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): long-standing discomfort (48-168 hr) without permanent injury e.g. failure of therapy with tricyclic antidepressants, atypical antipsychotic drugs; extrapyramidal side effects; parkinsonism; ADE resulting from increased bioavailability of tricyclic antidepressants, metoprolol, propafenone (central effects e.g. dizziness); INR 4.5-6.0; neutropenia 1.0-1.5x10^9/l; leucopenia 2.0-3.0x10^9/l; thrombocytopenia 50-75x10^9/l </td></tr><tr><td> IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele) </td><td> Reduce dose by 30% and monitor imipramine and desipramine plasma concentrations.   </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Minor clinical effect (S): QTc prolongation (&lt;450 ms men, &lt;470 ms women); INR increase &lt; 4.5. Kinetic effect (S). </td></tr><tr><td> UM (gene duplication in absence of inactive or decreased activity alleles) </td><td> Select alternative drug (e.g., citalopram, sertraline) or increase dose by 70% and monitor imipramine and desipramine plasma concentrations. </td><td> Published controlled studies of good quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Minor clinical effect (S): QTc prolongation (&lt;450 ms men, &lt;470 ms women); INR increase &lt; 4.5. Kinetic effect (S). </td></tr></table><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Allele Type </th><th> Alleles </th></tr><tr><td> active </td><td> *1, *2, *33, *35 </td></tr><tr><td> decreased activity </td><td> *9, *10, *17, *29, *36, *41  </td></tr><tr><td> inactive </td><td> *3-*8, *11-*16, *19-*21, *38, *40, *42 </td></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"good quality.\"</li><li>S: statistically significant difference.</li><li>Please see attached PDF for detailed information about the evaluated studies: <a href=\"/download.do?objCls=Attachment&amp;objId=imipramine_CYP2D6_271111.pdf\" title=\"link tip\">Imipramine CYP2D6</a></li></ul>"
}